Emblem Corp has 40% upside, Echelon Wealth says


With its financings now complete, Echelon Wealth Partners analyst Russell Stanley has refreshed his model assumptions on Emblem Corp. (Emblem Corp. Stock Quote, Chart, News: TSX:EMC) and finds the stock still has plenty of upside.

On November 15, Emblem Corp announce it had completed a bought deal financing that netted the company $28.8-million. The company said the vast majority of the proceeds would be used to fund its new 170,000 square-foot Paris Roads facility.

Stanley says although his estimates for Emblem Corp have been revised downward slightly, they are offset by a higher multiple.

“We last revised our 12-month target price in late August,” the analyst explains. “At that time, the adjusted average EV/C2019E EBITDA multiple for the peer group was approximately 7.0x. The peer group multiple has since climbed 80% to 12.6x. On that basis, we are increasing the multiple we use to value EMC from 8.5x to 12x, based on our EBITDA estimate for 2019 (EMC has a December 31 FYE).

In a research update to clients Tuesday, Stanley maintained his “Speculative Buy” rating and one-year price target of $2.25 on Emblem Corp., implying a return of 40 per cent at the time of publication.

Stanley thinks Emblem will generate Adjusted EBITDA of negative $6.9-million on revenue of $2.7-million in fiscal 2017. He expects those numbers will improve to EBITDA of negative $4.5-million on a topline of $10.9-million the following year.

More Cantech Cannabis

Tagged with: emc
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

This analyst just upped his price target on Knight Therapeutics

Research Capital analyst Andre Uddin raised his target on Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:GUD)… [Read More]

2 days ago

Kinaxis is rolling, this analyst says

National Bank Financial analyst Richard Tse maintained Kinaxis (Kinaxis Stock Quote, Chart, News, Analysts, Financials TSX:KXS) as a Top Pick… [Read More]

2 days ago

This analyst just raised his price target on Curaleaf

Beacon Securities analyst Russell Stanley said in a May 5 report that Curaleaf Holdings (Curaleaf Holdings Stock Quote, Chart, News,… [Read More]

2 days ago

Buy this pot stock for a double, analyst says

Roth Capital analyst Bill Kirk maintained a “Buy” rating and $5.00 target on High Tide (High Tide Stock Quote, Chart,… [Read More]

3 days ago

Cryoport stock is a buy, this analyst says

Roth Capital analyst Richard Baldry maintained a “Buy” rating and $15.00 target on Cryoport (Cryoport Stock Quote, Chart, News, Analysts,… [Read More]

3 days ago

Eupraxia wins new (US) $15.50 target at Leede Financial

Leede Financial analyst Douglas Loe raised his target on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials  NASDAQ:EPRX)… [Read More]

3 days ago